Paul Harari

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. ncbi request reprint Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234
    Paul M Harari
    Paul M Harari, University of Wisconsin Hospital, Madison, WI Jonathan Harris and Qiang Zhang, Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA Merrill S Kies, Jeffrey N Myers, and Kian Ang, MD Anderson Cancer Center, Houston, TX Richard C Jordan, University of California San Francisco, San Francisco Deepak Khuntia, Varian Medical Systems, Palo Alto, CA Maura L Gillison, The Ohio State University, Columbus Mitchell Machtay, Case Western Reserve University, Cleveland, OH Robert L Foote, Mayo Clinic, Rochester, MN Marvin Rotman, State University of New York Downstate Medical Center, Brooklyn, NY and William Straube, Washington University, St Louis, MO
    J Clin Oncol 32:2486-95. 2014
  2. pmc Intensity-modulated radiation therapy: emerging cancer treatment technology
    T S Hong
    Department of Human Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Br J Cancer 92:1819-24. 2005
  3. pmc Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers
    Shyhmin Huang
    Corresponding Author Paul M Harari, Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, K4 336, 600 Highland Avenue, Madison, WI 53792 0600
    Mol Cancer Ther 12:2772-81. 2013
  4. pmc Enhancement of radiation response with bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin Madison, Madison, WI, USA
    J Exp Clin Cancer Res 31:37. 2012
  5. ncbi request reprint Biology of interactions: antiepidermal growth factor receptor agents
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Clin Oncol 25:4057-65. 2007
  6. ncbi request reprint Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 10:428-32. 2004
  7. ncbi request reprint Radiation combined with EGFR signal inhibitors: head and neck cancer focus
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, 53792, USA
    Semin Radiat Oncol 16:38-44. 2006
  8. ncbi request reprint Promising new advances in head and neck radiotherapy
    P M Harari
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    Ann Oncol 16:vi13-vi19. 2005
  9. ncbi request reprint Epidermal growth factor receptor inhibition strategies in oncology
    P M Harari
    University of Wisconsin Medical School, Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue K4 332, Madison, Wisconsin 53792, USA
    Endocr Relat Cancer 11:689-708. 2004
  10. ncbi request reprint The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium
    Paul M Harari
    University of Wisconsin, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:S1-3. 2007

Collaborators

Detail Information

Publications63

  1. ncbi request reprint Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234
    Paul M Harari
    Paul M Harari, University of Wisconsin Hospital, Madison, WI Jonathan Harris and Qiang Zhang, Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA Merrill S Kies, Jeffrey N Myers, and Kian Ang, MD Anderson Cancer Center, Houston, TX Richard C Jordan, University of California San Francisco, San Francisco Deepak Khuntia, Varian Medical Systems, Palo Alto, CA Maura L Gillison, The Ohio State University, Columbus Mitchell Machtay, Case Western Reserve University, Cleveland, OH Robert L Foote, Mayo Clinic, Rochester, MN Marvin Rotman, State University of New York Downstate Medical Center, Brooklyn, NY and William Straube, Washington University, St Louis, MO
    J Clin Oncol 32:2486-95. 2014
    ....
  2. pmc Intensity-modulated radiation therapy: emerging cancer treatment technology
    T S Hong
    Department of Human Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
    Br J Cancer 92:1819-24. 2005
    ..This review focuses on basic principles, and highlights the clinical implementation of IMRT in head and neck and prostate cancer...
  3. pmc Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers
    Shyhmin Huang
    Corresponding Author Paul M Harari, Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, K4 336, 600 Highland Avenue, Madison, WI 53792 0600
    Mol Cancer Ther 12:2772-81. 2013
    ..The unique action mechanism of Sym004 warrants further investigation as a promising EGFR targeting agent combined with radiotherapy in cancer therapy...
  4. pmc Enhancement of radiation response with bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin Madison, Madison, WI, USA
    J Exp Clin Cancer Res 31:37. 2012
    ..Bevacizumab is a humanized monoclonal antibody that neutralizes VEGF. We examined the impact on radiation response by blocking VEGF signaling with bevacizumab...
  5. ncbi request reprint Biology of interactions: antiepidermal growth factor receptor agents
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    J Clin Oncol 25:4057-65. 2007
    ..Many questions remain to be answered, particularly with regard to how best combine EGFR inhibitors with conventional cancer therapies, and how to select those patients (tumors) most likely to benefit from EGFR inhibition strategies...
  6. ncbi request reprint Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Clin Cancer Res 10:428-32. 2004
  7. ncbi request reprint Radiation combined with EGFR signal inhibitors: head and neck cancer focus
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, 53792, USA
    Semin Radiat Oncol 16:38-44. 2006
    ..Much remains to be learned regarding the rational integration of EGFR inhibitors into cancer treatment regimens as well as methods to optimize the selection of patients most likely to benefit from EGFR inhibitor strategies...
  8. ncbi request reprint Promising new advances in head and neck radiotherapy
    P M Harari
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792, USA
    Ann Oncol 16:vi13-vi19. 2005
    ....
  9. ncbi request reprint Epidermal growth factor receptor inhibition strategies in oncology
    P M Harari
    University of Wisconsin Medical School, Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue K4 332, Madison, Wisconsin 53792, USA
    Endocr Relat Cancer 11:689-708. 2004
    ..It appears likely that EGFR inhibitors (and other rationally designed molecular growth inhibitors) will play a meaningful role in cancer therapy in the years to come...
  10. ncbi request reprint The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium
    Paul M Harari
    University of Wisconsin, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:S1-3. 2007
  11. ncbi request reprint Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer
    Paul M Harari
    University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:S25-7. 2007
    ....
  12. pmc Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Semin Radiat Oncol 19:63-8. 2009
    ....
  13. ncbi request reprint Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice?
    P M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine, Madison 53792 0600, USA
    J Clin Oncol 15:2050-5. 1997
    ..Nonetheless, its use has become a common community standard of practice in the United States (US). This report examines some of the factors that may have contributed to this phenomenon...
  14. ncbi request reprint EGFR-targeting monoclonal antibodies in head and neck cancer
    Igor Astsaturov
    Fox Chase Cancer Center, Philadelphia, PA, USA
    Curr Cancer Drug Targets 7:650-65. 2007
    ....
  15. ncbi request reprint Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling
    P M Harari
    Department of Human Oncology, University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA
    Semin Radiat Oncol 11:281-9. 2001
    ..A preview of current translational research efforts and early clinical trials focused primarily on radiation interaction is provided herein...
  16. ncbi request reprint Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation
    P M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 49:427-33. 2001
    ....
  17. pmc Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
    D L Wheeler
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Oncogene 27:3944-56. 2008
    ..Taken together these findings suggest a rationale for the clinical evaluation of combinatorial anti-HER targeting approaches in tumors manifesting acquired resistance to cetuximab...
  18. ncbi request reprint Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer
    Igor Astsaturov
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Expert Rev Anticancer Ther 6:1179-93. 2006
    ..Ongoing clinical trials will more clearly define the role for EGFR inhibitors in all treatment phases of HNSCC...
  19. ncbi request reprint Image guidance for precise conformal radiotherapy
    Thomas Rockwell Mackie
    Department of Human Oncology, University of Wisconsin, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 56:89-105. 2003
    ..To review the state of the art in image-guided precision conformal radiotherapy and to describe how helical tomotherapy compares with the image-guided practices being developed for conventional radiotherapy...
  20. ncbi request reprint Multiple daily fractionation radiotherapy schedules in lung cancer
    C A Schulz
    Department of Human Oncology, University of Wisconsin Medical School, 600 Highland Avenue, K4 310 CSC, Madison, WI 53792, USA
    Curr Oncol Rep 3:179-84. 2001
    ..Recent randomized trials suggest that such approaches may result not only in lowered rates of intrathoracic failure but also in improved survival...
  21. ncbi request reprint Helical tomotherapy: an innovative technology and approach to radiation therapy
    James S Welsh
    Department of Human Oncology, University of Wisconsin, School of Medicine, 600 Highland Avenue, Madison, WI 53792, USA
    Technol Cancer Res Treat 1:311-6. 2002
    ..e "conformal avoidance", the counterpart of conformal radiation therapy. Based on radiobiological principles that exploit the physical advantages of helical tomotherapy, several dosimetric and clinical investigations are underway...
  22. ncbi request reprint Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules
    Jack F Fowler
    Department of Human Oncology K4 316, University of Wisconsin, 600 Highland Ave, Madison, WI 53792, USA
    Radiother Oncol 69:161-8. 2003
    ..To investigate whether a predictive estimate can be obtained for a 'tolerance level' of acute oral and pharyngeal mucosal reactions in patients receiving head and neck radiotherapy, using an objective set of dose and time data...
  23. ncbi request reprint Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
    Desmond Curran
    Omega Research, Dublin, Ireland
    J Clin Oncol 25:2191-7. 2007
    ..In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab...
  24. ncbi request reprint Parotidectomy: ten-year review of 237 cases at a single institution
    David C Upton
    Department of Surgery, Division of Otolaryngology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Otolaryngol Head Neck Surg 136:788-92. 2007
    ....
  25. ncbi request reprint Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions
    Søren M Bentzen
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, K4 316 Clinical Sciences Center, Madison, WI 53792, USA
    Nat Clin Pract Oncol 4:172-80. 2007
    ..Further clinical progress in this field will require hypothesis-driven trials to ensure efficient identification of treatments with the most favorable risk:benefit ratio...
  26. ncbi request reprint Insulin-like growth factor-I receptor signaling blockade combined with radiation
    Gregory W Allen
    Department of Human Oncology, School of Medicine and Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Res 67:1155-62. 2007
    ..In summary, these results validate IGF-IR signal transduction blockade as a promising strategy to improve radiation therapy efficacy in human tumors, forming a basis for future clinical trials...
  27. ncbi request reprint Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)
    Shyh Min Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
    Cancer Res 62:4300-6. 2002
    ....
  28. ncbi request reprint Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center and School of Medicine, Madison, WI 53792, USA
    Semin Radiat Oncol 13:3-12. 2003
    ..However, we lack randomized trials that directly compare operative versus nonoperative treatment approaches and thus have consciously neglected review of the surgical series for purposes of this article...
  29. ncbi request reprint Bridging gaps in multidisciplinary head and neck cancer care: nursing coordination and case management
    Peggy A Wiederholt
    University of Wisconsin Paul P Carbone Comprehensive Cancer Center, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:S88-91. 2007
    ....
  30. ncbi request reprint Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison
    C Wesley Hodge
    Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 69:1032-41. 2007
    ....
  31. pmc Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 72:534-42. 2008
    ..To examine the interaction between panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, and radiation in head-and-neck squamous cell carcinoma and non-small-cell lung cancer cell lines and xenografts...
  32. ncbi request reprint Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development
    Paul M Harari
    Department of Human Oncology, University of Wisconsin School of Medicine, Madison 53792, USA
    Semin Radiat Oncol 12:21-6. 2002
    ..This report focuses primarily on the capacity of EGFR inhibitors to modulate cellular and overall tumor response to ionizing radiation...
  33. ncbi request reprint EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
    Ranee Mehra
    Department of Human Oncology, University of Wisconsin School of Medicine, 600 Highland Avenue K4 336, Madison, WI 53792, USA
    Curr Oncol Rep 10:176-84. 2008
    ..These promising results have prompted further study of EGFR inhibitors with radiation and cytotoxic chemotherapy to further increase the benefit of treatment for SCCHN...
  34. ncbi request reprint Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade
    Shyh Min Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792 0600, USA
    Mol Cancer Ther 1:507-14. 2002
    ..Taken together, these results provide evidence that C225 can suppress tumor-induced neovascularization and metastasis in SCC of the head and neck...
  35. doi request reprint Beware the swing and a miss: baseball precautions for conformal radiotherapy
    Paul M Harari
    Int J Radiat Oncol Biol Phys 70:657-9. 2008
  36. ncbi request reprint Clinical application of EGFR inhibitors in head and neck squamous cell cancer
    Igor Astsaturov
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Cancer Treat Res 139:135-52. 2008
  37. pmc Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program
    Christine H Chung
    Head and Neck Cancer Subcommittee, Translational Research Program, Radiation Therapy Oncology Group Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Int J Radiat Oncol Biol Phys 69:S67-78. 2007
    ..In this position paper we outline strategic plans to further promote translational research within the framework of the RTOG...
  38. ncbi request reprint Cetuximab (Imclone/Merck/Bristol-Myers Squibb)
    Merrill S Kies
    University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Curr Opin Investig Drugs 3:1092-100. 2002
    ..In May 2002, Lehman Brothers predicted global peak sales of US $2 billion [454652], while in the same month, Bear Stearns estimated that sales for Merck KGaA would reach 285 million Euros in 2007 [453500]...
  39. ncbi request reprint EGFR-targeting monoclonal antibodies in head and neck cancer
    Igor Astsaturov
    Fox Chase Cancer Center, Philadelphia, PA, USA
    Curr Cancer Drug Targets 6:691-710. 2006
    ....
  40. ncbi request reprint Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin Medical School, Madison, 53792 0600, USA
    Semin Radiat Oncol 16:59-64. 2006
    ..These approaches reviewed herein hold promise for improved radiation therapy efficacy and, ultimately, improved patient outcome...
  41. ncbi request reprint Intensity-modulated radiation therapy in the management of head and neck cancer
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, USA
    Curr Opin Oncol 17:231-5. 2005
    ..This review updates recent advances regarding the use of this emerging technology...
  42. ncbi request reprint Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Cancer Res 65:3328-35. 2005
    ..These data suggest that the erlotinib/radiation combination represents a strategy worthy of further examination in clinical trials...
  43. ncbi request reprint Modulation of radiation response by histone deacetylase inhibition
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 62:223-9. 2005
    ..In this study, we examine the capacity of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) to modulate radiation response in human tumor cell lines and explore potential mechanisms underlying these interactions...
  44. ncbi request reprint Planned postradiotherapy neck dissection: Rationale and clinical outcomes
    Gregory K Sewall
    Division of Otolaryngology Head and Neck Surgery, Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin 53792, USA
    Laryngoscope 117:121-8. 2007
    ....
  45. ncbi request reprint Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor
    Shyhmin Huang
    Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792 0600, USA
    Cancer Res 64:5355-62. 2004
    ..This approach suggests potential new strategies to maximize effective target inhibition, which may improve the therapeutic ratio for anti-EGFR-targeted therapies in developing clinical trials...
  46. ncbi request reprint Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade
    Jing Li
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792 0600, USA
    Int J Radiat Oncol Biol Phys 62:1477-85. 2005
    ..These data suggest that molecular inhibition of VEGFR2 alone, and in combination with radiation, can enhance tumor response through molecular targeting of tumor vasculature...
  47. ncbi request reprint Parotid area lymph node metastases from cutaneous squamous cell carcinoma: implications for diagnosis, treatment, and prognosis
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Hospital and Clinics, 600 Highland Avenue K4 332, Madison, WI 53792, USA
    Head Neck 27:851-6. 2005
    ..Parotid area lymph node metastasis from primary scalp and facial cutaneous cancers is a poorly recognized clinical entity partly because of the long time lapse between the index lesion and regional spread...
  48. ncbi request reprint The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Medical School, University Hospital and Clinics, 600 Highland Avenue K4 332, Madison, WI 53792, USA
    Int J Radiat Oncol Biol Phys 61:779-88. 2005
    ..This study provides a detailed analysis regarding the potential impact of daily setup variations on the overall integrity of H&N IMRT...
  49. ncbi request reprint Biologic basis for combining drugs with radiation
    George D Wilson
    Department of Radiation Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Semin Radiat Oncol 16:2-9. 2006
    ....
  50. ncbi request reprint Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    Int J Radiat Oncol Biol Phys 58:976-83. 2004
    ..To highlight some of the preclinical data that examine the interaction of epidermal growth factor receptor (EGFR) inhibitors with radiotherapy and chemotherapy...
  51. ncbi request reprint Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapy
    James S Welsh
    Department of Human Oncology, University of Wisconsin, Madison, Wisconsin, USA
    Technol Cancer Res Treat 5:465-79. 2006
    ....
  52. ncbi request reprint Clinical advancement of EGFR inhibitors in cancer therapy
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, Madison, USA
    Methods Mol Biol 327:189-202. 2006
    ..This chapter provides an overview of EGFR inhibitors and key clinical trial results that are helping to define a future role for these molecular agents in cancer treatment...
  53. ncbi request reprint Anti-EGFR therapy update: clinical experience and adverse event insights
    Paul M Harari
    Department of Human Oncology, University of Wisconsin, Madison, Wisconsin 53792, USA
    Oncology (Williston Park) 20:3-4. 2006
  54. ncbi request reprint Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck
    Nadine P Connor
    Department of Otolaryngology Head and Neck Surgery, University of Wisconsin Medical School, and William S Middleton Memorial Veterans Hospital, Madison, WI 53792 7375, USA
    Int J Radiat Oncol Biol Phys 65:1051-62. 2006
    ..Head-and-neck radiotherapy is associated with significant morbidities. Our purpose was to document impact of morbidities by use of multiple objective measures and health-related quality of life (HR-QOL)...
  55. ncbi request reprint Augmentation of radiation response with the vascular targeting agent ZD6126
    Tien Hoang
    Hematology Oncology Division, Ohio State University College of Medicine, Columbus, OH, USA
    Int J Radiat Oncol Biol Phys 64:1458-65. 2006
    ..The overall hypothesis was that simultaneous targeting of tumor cells (radiation) and tumor vasculature (ZD6126) might enhance tumor cell killing...
  56. ncbi request reprint Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  57. ncbi request reprint Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations
    Paul M Harari
    Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA
    Curr Probl Cancer 28:7-40. 2004
  58. ncbi request reprint Precautions in the use of intensity-modulated radiation therapy
    James S Welsh
    Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
    Technol Cancer Res Treat 4:203-10. 2005
    ..Here we discuss some of the precautions worthy of consideration when using IMRT and how these might be addressed in routine practice...
  59. ncbi request reprint Megavoltage computed tomography: an emerging tool for image-guided radiotherapy
    Theodore S Hong
    Department of Human Oncology, University of Wisconsin Medical School, Madison, WI, USA
    Am J Clin Oncol 30:617-23. 2007
    ..In this study, we assessed the image-quality, absorbed radiation doses, and clinical practicality of MVCT from our helical tomotherapy prototype unit...
  60. ncbi request reprint Tumor volume as a prognostic factor in oropharyngeal squamous cell carcinoma treated with primary radiotherapy
    Mark J Been
    Department of Surgery, Division of Otolaryngology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
    Laryngoscope 118:1377-82. 2008
    ..The purpose of this study was to conduct an institutional review analyzing the correlation between tumor volume and locoregional control of oropharyngeal squamous cell cancer treated with primary radiotherapy...
  61. ncbi request reprint ACCO: ASCO core curriculum outline
    Hyman B Muss
    Education, Science and Career Development, American Society of Clinical Oncology, 1900 Duke Street, Suite 200, Alexandria, VA 22314, USA
    J Clin Oncol 23:2049-77. 2005
  62. ncbi request reprint Introduction
    Paul M Harari
    Semin Radiat Oncol 16:1. 2006
  63. ncbi request reprint Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition
    Prakash Chinnaiyan
    Department of Human Oncology, University of Wisconsin, Madison, WI 53792 0600, USA
    Int J Cancer 118:1041-50. 2006
    ....

Research Grants5

  1. EGFR/Radiation Response and Resistance Interactions
    Paul Harari; Fiscal Year: 2006
    ..In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ..
  2. EGFR/Radiation Responses and Resistance Interactions
    Paul Harari; Fiscal Year: 2007
    ..In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ..
  3. EGFR/Radiation Responses and Resistance Interactions
    Paul Harari; Fiscal Year: 2009
    ..In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ..
  4. EGFR/Radiation Response and Resistance Interactions
    Paul M Harari; Fiscal Year: 2010
    ..In this research proposal, we seek to increase the percentage of cancer patients who benefit from leading cancer drugs through the identification and disabling of specific tumor cell molecules that promote treatment resistance. ..